Zacks Research Predicts Lower Earnings for Gilead Sciences

Zacks Research has updated its earnings estimates for Gilead Sciences, trimming Q1 2026 EPS to $1.74 and lowering the full-year 2026 forecast to $8.29, which is below the street consensus. Despite this modest downgrade, multiple brokers maintain positive ratings and have raised price targets, and Gilead recently exceeded Q4 EPS expectations and increased its dividend. The company faces mixed sentiment due to positive regulatory developments for acquisitions and HIV prevention drugs, alongside a halted clinical trial and notable insider selling.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin